דפו-מדרול עם לידוקאין ישראל - עברית - Ministry of Health

דפו-מדרול עם לידוקאין

pfizer pfe pharmaceuticals israel ltd - lidocaine as hydrochloride; methylprednisolone acetate - תרחיף להזרקה - lidocaine as hydrochloride 10 mg/ml; methylprednisolone acetate 40 mg/ml - methylprednisolone, combinations - lidocaine - depo-medrol with lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.

Colleague Infusion Pumps ישראל - עברית - Ministry of Health

colleague infusion pumps

טבע מדיקל (שיווק) בע"מ - אחות - the colleague pump is designed to deliver infusion therapies via clinically acceptable routes of administration, including intravenous, intra-arterial, epidural, and subcutaneous routes.

ChemSAT System ישראל - עברית - Ministry of Health

chemsat system

איי. אל אמרגו ישראל בע"מ - רופא - hepatic delivery system for percutaneous intra-arterial administration of a chemotherapeutic agent (melphalan hydrochlorid)

סימזיה ישראל - עברית - Ministry of Health

סימזיה

neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol

אילומדין ישראל - עברית - Ministry of Health

אילומדין

bayer israel ltd - iloprost - תרכיז להכנת תמיסה לאינפוזיה - iloprost 0.1 mg/ml - iloprost - iloprost - peripheral arterial occlusive disease (stage 3 and 4 of fontaine's classification) in advanced arteriosclerosis, in whom surgery or angioplasty therapy is not possible.thromboangitis obliterans (buerger's disease) with critical limb ischemia in cases where revascularisation is not indicated and severe disabling raynaud's phenomenon .

יורוקינאז מדאק 1,000,000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 1,000,000 iu

tzamal bio-pharma ltd - urokinase 1000000 iu - powder for solution for injection - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

טרקליר 62.5 מג ישראל - עברית - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

אביטרקסט תמיסה 1 גרם/10 מ"ל ישראל - עברית - Ministry of Health

אביטרקסט תמיסה 1 גרם/10 מ"ל

salomon,levin & elstein ltd - methotrexate 1000 mg / 10 ml - solution for injection - methotrexate - antineoplastic chemotherapy.psoriasis. rheumatoid arthritis.

סימפוני ישראל - עברית - Ministry of Health

סימפוני

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.